EDI-048(EDI-048) - 药物靶点：CpPI(4)K_在研适应症：隐孢子虫病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

EDI 048、EDI048

靶点

CpPI(4)K

作用方式

抑制剂

作用机制

CpPI(4)K抑制剂(隐孢子虫PI4K蛋白抑制剂)

治疗领域

感染消化系统疾病

在研适应症

隐孢子虫病

非在研适应症-

原研机构

Novartis AG

在研机构

Novartis Pharmaceuticals Canada, Inc.

Novartis AG

Novartis Pharmaceuticals Corp.

非在研机构-

权益机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C25H21ClN4O4

InChIKeyUUGWSUYPJGPKKF-UHFFFAOYSA-N

CAS号2767264-57-1

关联

3

项与 EDI-048 相关的临床试验

NCT07249463

/ Recruiting临床2期

A Randomized, Placebo-controlled, Participant- and Investigator-blinded Study to Assess the Efficacy and Safety and Tolerability of EDI048 in a Cryptosporidium Controlled Human Infection Model (CHIM) in Healthy Participants

This study has the purpose to demonstrate prospect of benefit of EDI048 on clinical signs and symptoms of cryptosporidiosis to facilitate trial in target population, pediatric patients.
This study aims to investigate the efficacy of a new chemical entity, EDI048, in a controlled human infection model of cryptosporidiosis induced by administration of ABO809 in healthy adults, who become symptomatic with disease thereby demonstrating a prospect of benefit for use of EDI048 in children afflicted with cryptosporidiosis.

开始日期2025-12-08

申办/合作机构

Novartis Pharmaceuticals Canada, Inc.

NCT05275855

/ Completed临床1期

A First-in-human, Randomized, Participant and Investigator Blinded, Placebo Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of EDI048 in Healthy Volunteers

A first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses and multiple ascending doses of EDI048 administered orally in healthy volunteers.

开始日期2022-04-29

申办/合作机构

Novartis Pharmaceuticals Corp.

ISRCTN38693215

/ Recruiting临床1期

A first-in-human, randomized, participant and investigator blinded, placebo controlled, single and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of EDI048 in healthy volunteers

开始日期2022-04-25

申办/合作机构

Novartis Pharma AG

100 项与 EDI-048 相关的临床结果

登录后查看更多信息

100 项与 EDI-048 相关的转化医学

登录后查看更多信息

100 项与 EDI-048 相关的专利（医药）

登录后查看更多信息

100 项与 EDI-048 相关的药物交易

登录后查看更多信息